全文获取类型
收费全文 | 4118篇 |
免费 | 335篇 |
国内免费 | 105篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 138篇 |
妇产科学 | 50篇 |
基础医学 | 243篇 |
口腔科学 | 196篇 |
临床医学 | 502篇 |
内科学 | 491篇 |
皮肤病学 | 179篇 |
神经病学 | 19篇 |
特种医学 | 52篇 |
外科学 | 308篇 |
综合类 | 505篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 265篇 |
眼科学 | 74篇 |
药学 | 1296篇 |
2篇 | |
中国医学 | 92篇 |
肿瘤学 | 72篇 |
出版年
2024年 | 3篇 |
2023年 | 51篇 |
2022年 | 72篇 |
2021年 | 144篇 |
2020年 | 153篇 |
2019年 | 147篇 |
2018年 | 167篇 |
2017年 | 150篇 |
2016年 | 137篇 |
2015年 | 150篇 |
2014年 | 235篇 |
2013年 | 426篇 |
2012年 | 274篇 |
2011年 | 243篇 |
2010年 | 176篇 |
2009年 | 193篇 |
2008年 | 185篇 |
2007年 | 160篇 |
2006年 | 172篇 |
2005年 | 133篇 |
2004年 | 128篇 |
2003年 | 137篇 |
2002年 | 117篇 |
2001年 | 85篇 |
2000年 | 73篇 |
1999年 | 60篇 |
1998年 | 49篇 |
1997年 | 47篇 |
1996年 | 61篇 |
1995年 | 40篇 |
1994年 | 37篇 |
1993年 | 41篇 |
1992年 | 32篇 |
1991年 | 29篇 |
1990年 | 25篇 |
1989年 | 34篇 |
1988年 | 20篇 |
1987年 | 20篇 |
1986年 | 14篇 |
1985年 | 21篇 |
1984年 | 25篇 |
1983年 | 17篇 |
1982年 | 11篇 |
1981年 | 9篇 |
1980年 | 15篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 12篇 |
1976年 | 6篇 |
1975年 | 3篇 |
排序方式: 共有4558条查询结果,搜索用时 78 毫秒
91.
《Expert opinion on pharmacotherapy》2013,14(8):1373-1385
Importance of the field: Chronic endobronchial infection in cystic fibrosis (CF) leads to progressive lung function loss and respiratory failure. Most adult CF patients are infected with Pseudomonas aeruginosa, an important predictor of mortality. Suppressing chronic P. aeruginosa infection with inhaled antibiotics is standard of care for CF patients.Areas covered in this review: This review describes the development (2003 – 2010) of aztreonam lysine 75 mg powder and solvent for nebulizer solution (AZLI; Cayston®), an aerosolized formulation of the monobactam antibiotic aztreonam.What the reader will gain: AZLI was studied in patients with CF and chronic P. aeruginosa airway infection. In placebo-controlled trials, AZLI improved respiratory symptoms, increased forced expiratory volume in 1 sec (FEV1), decreased sputum P. aeruginosa density, and was well tolerated. An open-label follow-on trial of nine ‘on/off’ courses showed that AZLI was safe and the effect durable with repeated administration. AZLI was recently approved for use in CF patients in Australia and the USA, and conditionally approved in Canada and the European Union. AZLI is given three times daily for 28 days (2 – 3 min/dose), followed by 28 days off-drug. AZLI is used only with the Altera Nebulizer System?, which provides appropriate particle size and small airway deposition, and has excellent portability.Take home message: AZLI is a new therapy that is safe and effectively improves respiratory symptoms and FEV1 in patients with CF. 相似文献
92.
《Expert opinion on pharmacotherapy》2013,14(3):323-329
Introduction: Cystic fibrosis (CF) is an inherited rare disease characterised by recurrent pulmonary infection, pancreatic malabsorption and a number of other multisystem effects. In the past few years new drugs specifically designed to treat CF have entered the pipeline, and some are now used in clinical practice. Areas covered: Clinical trial results from CF trials reported or ongoing within the last 3 years are discussed. A literature and trials registry search of trials and meta-analyses involving patients with CF was conducted, from which the most exciting developments were selected. Expert opinion: Drugs to address the basic defect in CF have finally come to market, albeit for a limited number of patients with a specific genotype. Traditional areas of CF therapeutics continue to be developed, with modest success, including drugs to modulate the airway surface liquid, new pancreatic supplements, antibiotics and new treatments for endocrine complications of CF. 相似文献
93.
《Gut microbes》2013,4(6):541-548
Occurrence of resistance, especially to clarithromycin, renders the standard triple therapy used to cure Helicobacter pylori infection ineffective. This review presents the bacteriological and pharmacological basis for H. pylori therapy and the current recommendations. The third-line treatment must be based on clarithromycin susceptibility testing. If the bacteria are still susceptible, failure may come from problems of compliance, hyperacidity or high bacterial load which can be overcome. If the bacteria are resistant, different regimens must be considered, including bismuth and non-bismuth-based quadruple therapies (sequential or concomitant), as well as triple therapies where amoxicillin is administered several times a day to obtain an optimal concentration at the gastric mucosal level. The treatments are becoming more and more complex and ecologically unsatisfactory, waiting for new agents or vaccines. 相似文献
94.
《Expert review of anti-infective therapy》2013,11(5):761-769
Solid-organ transplantation has become a widely accepted treatment modality for end-stage diseases. With the advent of newer and more potent immunosuppressive regimens, graft survival has improved, but at the expense of an increased risk for the development of infections secondary to bacterial, fungal, viral and parasitic pathogens. Prevention of such infectious complications with effective, well-tolerated and cost-effective antimicrobials would be ideal to improve the outcome of transplant patients. Cytomegalovirus is the most common cause of viral infections. Herpes simplex virus, Varicella-zoster virus, Epstein–Barr virus and others are also significant pathogens. Fungal infections are associated with the highest mortality rates. This review summarizes the most relevant data pertaining to the current understanding of infection prevention for solid-organ transplant recipients. 相似文献
95.
《Expert review of anti-infective therapy》2013,11(6):887-895
Virtually all life forms express short antimicrobial cationic peptides as an important component of their innate immune defenses. They serve as endogenous antibiotics that are able to rapidly kill an unusually broad range of bacteria, fungi and viruses. Consequently, considerable efforts have been expended to exploit the therapeutic potential of these antimicrobial peptides. Within the last couple of years, it has become increasingly clear that many of these peptides, in addition to their direct antimicrobial activity, also have a wide range of functions in modulating both innate and adaptive immunity. For one class of antimicrobial peptides, such as the human defensins, their primary role may even be as immunomodulators. These properties potentially provide entirely new therapeutic approaches to anti-infective therapy. 相似文献
96.
Magne Aldrin Ragnhild Raastad Ingunn Fride Tvete Dag Berild Arnoldo Frigessi Truls Leegaard Dominique L. Monnet Mette Walberg Fredrik Müller 《Statistics in medicine》2013,32(8):1407-1418
Association between previous antibiotic use and emergence of antibiotic resistance has been reported for several microorganisms. The relationship has been extensively studied, and although the causes of antibiotic resistance are multi‐factorial, clear evidence of antibiotic use as a major risk factor exists. Most studies are carried out in countries with high consumption of antibiotics and corresponding high levels of antibiotic resistance, and currently, little is known whether and at what level the associations are detectable in a low antibiotic consumption environment. We conduct an ecological, retrospective study aimed at determining the impact of antibiotic consumption on antibiotic‐resistant Pseudomonas aeruginosa in three hospitals in Norway, a country with low levels of antibiotic use. We construct a sophisticated statistical model to capture such low signals. To reduce noise, we conduct our study at hospital ward level. We propose a random effect Poisson or binomial regression model, with a reparametrisation that allows us to reduce the number of parameters. Inference is likelihood based. Through scenario simulation, we study the potential effects of reduced or increased antibiotic use. Results clearly indicate that the effects of consumption on resistance are present under conditions with relatively low use of antibiotic agents. This strengthens the recommendation on prudent use of antibiotics, even when consumption is relatively low. Copyright © 2012 John Wiley & Sons, Ltd. 相似文献
97.
Judit Müller Miklós Garami Tamás Constantin Marianne Schmidt György Fekete Gábor Kovács 《Pediatric hematology and oncology》2013,30(4):277-284
The aim of this retrospective study was to evaluate the clinical effectiveness of meropenem in immunocompromised children. Between January 1998 and December 2002 in the hemato-oncological units of our hospital meropenem was used in 87 febrile events diagnosed in 55 patients, and 328 bacterial cultures were evaluated. Microorganisms were detected and identified in 64 of the 328 hemocultures; there was a predominance of gram-positive strains (67%). In 49.4% the infection was documented microbiologically. In 16 additional cases the infection was proven clinically and 32.2% of the episodes were considered to be fever of unknown origin. The success rate of the meropenem therapy—excluding the proven fungal or coagulase-negative Staphylococcus infections—was 72.9% and for the whole cohort 49.4%. The results demonstrate that meropenem is effective and well-tolerated when used for the treatment of neutropenic cancer children. 相似文献
98.
《International journal of radiation biology》2013,89(8):839-845
Purpose:?An unbiased approach of drug discovery through high-throughput screening (HTS) of libraries of chemically defined and bioactive small molecule compounds was used to identify modulators of radiation injury with an emphasis on radioprotectors and mitigators rather than radiosensitisers. Assay system endpoints included radiation-induced genotoxicity and DNA damage in yeast and apoptosis in murine lymphocytes. Large-scale data mining of chemically diverse libraries identified agents that were effective with all endpoints. HTS of bioactive compound libraries against murine lymphocytes profiled tetracycline and fluoroquinolone antibiotics and cyclopiazonic acid as having activity, and structure-activity analysis showed a common pharmacophore. Purine nucleosides, the interferon inducer tilorone, and linoleic acid were also identified as potential mitigators of radiation damage that often were also radioprotective. Many of these compounds enhance DNA repair, have anti-inflammatory activity, and stimulate hematopoiesis. Selected compounds within these initial verified hits from both types of libraries identified potent mitigators of lethal whole body irradiation (WBI) in mice.Conclusion:?In spite of the fact that in vitro HTS has limitations and is unable to fully recapitulate all aspects of the complex in vivo acute radiation response, it identified several classes of molecules that had activity as radioprotectors and radiomitigators of the hematopoietic system in vivo. In the future, addition of 3-dimensional (3-D) or stem cell cultures or pathway analysis, may improve the power of HTS, but our findings indicate that common, evolutionary conserved, canonical pathways can be identified that could be exploited to mitigate radiation-induced defects. 相似文献
99.
《Acta orthopaedica》2013,84(5):566-569
Three cases of osteomyelitis of the patella are reported. One presented as an acute septic arthritis and another developed a sterile arthritis despite antibiotics. The clinical signs, diagnosis and treatment are discussed. Treatment with rest and antibiotics failed to cure the disease. in all three cases a sequestrectomy was carried out resulting in healing of the affected patella and recovery of knee mobility. 相似文献
100.
Wooseong Kim Gabriel Lambert Hendricks Kiho Lee 《Expert opinion on drug discovery》2017,12(6):625-633
Introduction: The emergence of antibiotic-resistant and -tolerant bacteria is a major threat to human health. Although efforts for drug discovery are ongoing, conventional bacteria-centered screening strategies have thus far failed to yield new classes of effective antibiotics. Therefore, new paradigms for discovering novel antibiotics are of critical importance. Caenorhabditis elegans, a model organism used for in vivo, offers a promising solution for identification of anti-infective compounds.Areas covered: This review examines the advantages of C. elegans-based high-throughput screening over conventional, bacteria-centered in vitro screens. It discusses major anti-infective compounds identified from large-scale C. elegans-based screens and presents the first clinically-approved drugs, then known bioactive compounds, and finally novel small molecules.Expert opinion: There are clear advantages of using a C. elegans-infection based screening method. A C. elegans-based screen produces an enriched pool of non-toxic, efficacious, potential anti-infectives, covering: conventional antimicrobial agents, immunomodulators, and anti-virulence agents. Although C. elegans-based screens do not denote the mode of action of hit compounds, this can be elucidated in secondary studies by comparing the results to target-based screens, or conducting subsequent target-based screens, including the genetic knock-down of host or bacterial genes. 相似文献